The treatment “Wegovi” is given to obese people by injection, and the media described it as a game-changer. The drug, which is considered the first of its kind, was developed by Novo Nordisk. The new drug helps control chronic weight gain in adults who are obese, or those who are overweight and have an associated health condition, such as type 2 diabetes.
The Food and Drug Administration says this drug is intended for patients with a BMI of 27 kg/m2 or greater who have at least one weight-related disease, or a BMI of 30 kg/m2 or greater.
The drug works at maximum capacity in the case of a low-calorie diet and an active exercise regimen. The drug is taken as an injection under the skin, once a week.
According to FDA official John Charites, “Today’s approval offers adults (who are) obese or overweight a useful new treatment option for inclusion in a weight management program.” The drug relies on the active substance “semaglutide”, from which drugs are made to control type 2 diabetes.